

REVIEW ARTICLE

Platelet-Rich Fibrin and Soft Tissue Wound Healing: A Systematic Review

Richard J. Miron, DDS, MSc, PhD, dr. med. dent.,¹ Masako Fujioka-Kobayashi, DDS, PhD,¹⁻³ Mark Bishara, DDS,⁴ Yufeng Zhang, DDS, MD, PhD,⁵ Maria Hernandez, DDS, MS,¹ and Joseph Choukroun, MD⁶

The growing multidisciplinary field of tissue engineering aims at predictably regenerating, enhancing, or replacing damaged or missing tissues for a variety of conditions caused by trauma, disease, and old age. One area of research that has gained tremendous awareness in recent years is that of platelet-rich fibrin (PRF), which has been utilized across a wide variety of medical fields for the regeneration of soft tissues. This systematic review gathered all the currently available *in vitro*, *in vivo*, and clinical literature utilizing PRF for soft tissue regeneration, augmentation, and/or wound healing. In total, 164 publications met the original search criteria, with a total of 48 publications meeting inclusion criteria (kappa score = 94%). These studies were divided into 7 *in vitro*, 11 *in vivo*, and 31 clinical studies. In summary, 6 out of 7 (85.7%) and 11 out of 11 (100%) of the *in vitro* and *in vivo* studies, respectively, demonstrated a statistically significant advantage for combining PRF to their regenerative therapies. Out of the remaining 31 clinical studies, a total of 8 reported the effects of PRF in a randomized clinical trial, with 5 additional studies (13 total) reporting appropriate controls. In those clinical studies, 9 out of the 13 studies (69.2%) demonstrated a statistically relevant positive outcome for the primary endpoints measured. In total, 18 studies (58% of clinical studies) reported positive wound-healing events associated with the use of PRF, despite using controls. Furthermore, 27 of the 31 clinical studies (87%) supported the use of PRF for soft tissue regeneration and wound healing for a variety of procedures in medicine and dentistry. In conclusion, the results from the present systematic review highlight the positive effects of PRF on wound healing after regenerative therapy for the management of various soft tissue defects found in medicine and dentistry.

Keywords: platelets, fibrin, PRP, PRF, angiogenesis, vascularization

Introduction

THE MULTIDISCIPLINARY FIELD of tissue engineering aims at predictably repairing, regenerating, or restoring damaged and supporting tissues, including cell, tissue, and organs, due to an assortment of biological conditions, including congenital abnormalities, injury, disease, and/or aging.¹⁻⁴ During their regeneration, one key aspect involves the ingrowth of a vascular source that is capable of supporting cellular function and future tissue development by maintaining a viable exchange of nutrients through blood vessels.⁵ Although the majority of tissue engineering scaffolds are avascular by nature, it remains essential that all

regenerative strategies focus on the development of a vascular network to obtain successful clinical outcomes and regeneration of either soft or hard tissues.⁵

Wound healing, which is defined as the natural restorative response to tissue injury, involves a cascade of complex, orderly, and elaborate events involving many cell types guided by the release of soluble mediators and signals that are capable of influencing the homing of circulating cells to damaged tissues.⁶ Typically, wound-healing events are divided into four overlapping phases, including hemostasis, inflammation, proliferation, and remodeling.⁷⁻⁹ Platelets have been shown to be important cells regulating the hemostasis phase through vascular obliteration and facilitating

¹Department of Periodontology, Nova Southeastern University, Fort Lauderdale, Florida.

²Cranio-Maxillofacial Surgery, Bern University Hospital, Inselspital, Bern, Switzerland.

³Department of Oral Surgery, Clinical Dentistry, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan.

⁴West Bowmanville Family Dental, Ontario, Canada.

⁵Department of Oral Implantology, University of Wuhan, Wuhan, China.

⁶Pain Clinic, Nice, France.

fibrin clot formation.⁶ Although debate has been ongoing as to whether platelets should be regarded as cell fragments or whole cells,¹⁰ it is well known that they are responsible for the activation and release of important biomolecules, including platelet-specific proteins, growth factors including platelet-derived growth factor (PDGF), coagulation factors, adhesion molecules, cytokines/chemokines, and angiogenic factors that are capable of stimulating the proliferation and activation of cells involved in wound healing, including fibroblasts, neutrophils, macrophages, and mesenchymal stem cells (MSCs).¹¹ For these reasons, the use of platelet concentrates has been utilized in modern medicine for more than four decades due to their hypothesized impact on tissue regeneration by facilitating angiogenesis and various additional phases during wound healing, including cell recruitment, proliferation, remodeling, and differentiation. Later, we describe how tissue-engineering constructs have utilized various platelet concentrates to speed wound healing of either soft or hard tissues.

Platelet concentrates: from platelet-rich plasma to platelet-rich fibrin

Autologous platelet-rich plasma (PRP) was first developed in the early 1970s and was made popular in the 1980s.^{12,13} The first generation of PRP was introduced by mixing collected blood with thrombin and excess calcium, resulting in activated platelets trapped within a fibrin network. Since then, different platelet preparation protocols are now available and traditionally isolated by a dual-speed centrifugation process. The first spin separates red blood cells from plasma and buffy coat. Thereafter, the platelet plug is typically separated from the platelet-poor plasma in a second spin cycle generating PRP, a platelet concentrate with up to 6–8 times the concentration of growth factors when compared with whole blood.¹⁴ These platelets have been shown to secrete high levels of bioactive substances that slowly diffuse to the surrounding micro-environment facilitating tissue regeneration.^{15–19} Much advancement has since been made in the medical field by various groups, who demonstrated that PRP could further enhance surgical wound healing of either soft or hard tissues.^{15,20,21} Despite its widespread use, one of the reported drawbacks was the use of anti-coagulation factors delaying normal wound-healing events.

Due to these reported limitations, further research was focused on developing a second-generation platelet concentrate without utilizing anti-coagulation factors. As such, a platelet concentrate lacking coagulation factors, later

termed platelet-rich fibrin (PRF), was developed due to its anticipated properties in tissue regeneration and wound healing.^{22–25} PRF (also termed leukocyte-PRF), in addition, contains more white blood cells (WBCs), necessary cells that are important during the wound-healing process (Fig. 2).^{17,26–30} Furthermore, since WBCs, including neutrophils and macrophages, are one of the first cell types found in wounded sites, their role also includes to phagocytize debris, microbes, and necrotic tissue, thereby preventing infection. Macrophages are also key cells derived from the myeloid lineage and are considered one of the key cells implicated in growth factor secretion during wound healing, including transforming growth factor beta (TGF-beta), PDGF, and vascular endothelial growth factor (VEGF) (Fig. 2). These cells, together with neutrophils and platelets, are key players in wound healing and in combination with their secreted growth factors/cytokines are capable of facilitating tissue regeneration, new blood vessel formation (angiogenesis), and prevention of infection.^{22–25,28} To date, numerous studies have investigated the regenerative potential of PRF in various medical situations. The aim of this article was to systematically characterize the potential for PRF to influence soft tissue wound healing. A systematic search was carried out, including all *in vitro*, *in vivo*, and clinical studies performed on PRF to date dealing with soft tissue regeneration, wound healing, and/or angiogenesis after treatment with PRF.

Methods

Development of a protocol

A protocol including all aspects of a systematic review methodology was developed before commencing the review. This included a definition of the focused question; a defined search strategy; study inclusion criteria; determination of outcome measures; screening methods, data extraction, and analysis; and data synthesis.


Defining the focused question

The following focused question was defined: “Does platelet rich fibrin (PRF) affect/induce soft tissue regeneration and/or soft tissue wound healing?”

Search strategy

Using the MEDLINE database, the literature was searched for articles published up to and including April 7th, 2016 (Figure 1). Combinations of several search terms were

FIG. 1. Flow chart of the screened relevant publications.






FIG. 2. Representative diagram of the cell types, extracellular matrix components, and bioactive molecules found in PRF. PRF, platelet-rich fibrin. Color images available online at www.liebertpub.com/teb

applied to identify appropriate studies (Table 1). Reference lists of review articles and of the included articles in the present review were screened.

Criteria for study selection and inclusion

Study selection considered only articles published in English, describing *in vitro*, *in vivo*, and human clinical studies evaluating the effect of PRF on soft tissue wound healing. All *in vitro* studies were included on fibroblasts, endothelial cells, keratinocytes, and/or periodontal ligament fibroblasts. All *in vivo* data specifically characterizing the effects of PRF on soft tissue wound healing were included. All human studies reporting the effects of PRF were also included. Human studies were not limited to randomized clinical trials.

Outcome measure determination

The primary outcome of interest was to determine the effect in percentage increases that PRF is capable of inducing soft tissue regeneration and wound-healing events.

TABLE 1. SEARCH TERMS USED TO IDENTIFY THE RELEVANT STUDIES

Search terms

"Platelet Rich Fibrin" OR "PRF" OR "Platelet-Rich Fibrin" OR "Leukocyte Platelet Rich Fibrin" OR "Leukocyte Platelet-Rich Fibrin" OR "LPRF" OR "L-PRF" OR "Advanced Platelet Rich Fibrin" OR "Advanced PRF" OR "A-PRF" OR "APRF"

AND

"Soft Tissue Regeneration" OR "Soft Tissue Wound Regeneration" OR "Soft Tissue Wound-Healing" OR "Wound Healing" OR "Wound-Healing" OR "Soft Tissue Augmentation" OR "Angiogenesis"

The outcome measures were separated into (1) *in vitro* studies, (2) animal studies, and (3) clinical studies. Since large variability in the outcomes measured was performed by the various groups working across several fields of medicine, a meta-analysis was not considered. Outcomes were summarized in Tables 2–4 for the various *in vitro*, *in vivo*, and clinical studies according to the specific effect of PRF on soft tissue wound healing.

Screening method

Titles and abstracts of the selected studies were independently screened by two reviewers (R.J.M. and M.F.-K.) on April 7th, 2016. The screening was based on the question: "What effect does platelet rich fibrin (PRF) have on soft tissue regeneration and/or wound healing?" Full text articles were obtained if the response to the screening question was "yes" or "uncertain". The level of agreement between reviewers was determined by kappa scores according to company software instructions (GraphPad Software, Inc., La Jolla, CA, <http://graphpad.com/quickcalcs/kappa1.cfm>). Disagreement regarding inclusion was resolved by discussion between authors. For necessary missing data, the authors of the studies were contacted. Articles referring strictly to use in tendons, and orthopedic/bone uses were excluded if soft tissue wound-healing events were not investigated/discussed. Furthermore, review articles and clinical cases with no measurable endpoint were excluded.

Data extraction and analysis

The following data were extracted: general characteristics (authors, year of publication), PRF centrifugation characteristics/protocols, evaluation characteristics (amount of PRF utilized, volume, period, outcome measures), methodological characteristics (study design, methodological quality), and conclusions. Because of the heterogeneity

TABLE 2. *IN VITRO* STUDIES EVALUATING THE EFFECTS OF PLATELET-RICH FIBRIN ON SOFT TISSUE REGENERATION AND/OR WOUND HEALING

Author	Year	Cell type	Centrifugation protocol	Findings/conclusions
Lundquist <i>et al.</i>	2008	Human dermal fibroblasts	400 g for 10 min	PRF induced higher fibroblast proliferation when compared with fibrin sealant and recombinant PDGF. Furthermore, PRF protected against proteolytic degradation of endogenous fibrogenic factors important for wound healing.
Roy <i>et al.</i>	2011	Endothelial cells	1100 g for 6 min (with trisodium citrate) followed by 4500 g for 25 min (with CaCl ₂)	PRF induced endothelial cell mitogenesis via extracellular signal-regulated protein kinase activation pathway.
Clipet <i>et al.</i>	2012	Keratinocytes, fibroblasts	400 g for 12 min	Soluble growth factors from PRF induced cell viability and proliferation differentiation.
Lundquist <i>et al.</i>	2013	Human dermal fibroblasts	3000 g for 8 min followed by 2 min at 3000 g	Fibrocytes (important cells for acute wound healing) were grown from within PRF patches, implicating their role in wound healing and soft tissue regeneration.
Ghanaati <i>et al.</i>	2014	PRF clots	150 g for 14 min	Introduction of A-PRF: By decreasing the rpm/g-force while increasing the centrifugation time in A-PRF, an enhanced presence of neutrophilic granulocytes and macrophages, cells were implicated in wound healing.
Vahabi <i>et al.</i>	2015	Gingival fibroblasts	400 g for 12 min	PRGF induced significantly higher gingival fibroblast proliferation at 48 and 72 h when compared with PRF.
Bayer <i>et al.</i>	2016	Primary keratinocytes	2000 g for 10 min followed by 2000 g for 10 min	PRF contains some anti-inflammatory/microbial effects in human keratinocytes through the expression of an antimicrobial peptide hBD-2.

PRF, platelet-rich fibrin; PDGF, platelet-derived growth factor; A-PRF, advanced-PRF; PRGF, plasma rich in growth factors.

of the included studies (study design, *in vitro* vs. animal vs. clinical studies, investigated parameters, materials used, evaluation methods, outcome measures, observation periods), no mean differences could be calculated, and consequently, no quantitative data synthesis and meta-analysis could be performed. Instead, the data are reported in a systematic fashion characterizing all available literature to date. Therefore, data were extracted from the reviewed articles and summarized in separate tables based on the various *in vitro*, *in vivo*, and clinical studies and outcome measures employed.

Results

In vitro studies evaluating the effects of PRF on cell behavior

The evaluation of PRF on the cells found during soft tissue regeneration and/or wound healing has been investigated in seven *in vitro* studies to date (Table 2). The effects of PRF have been investigated on (1) cell behavior of fibroblasts involved in soft tissue wound healing, (2) endothelial cells, and (3) growth factor release from various PRF formulations.

Effects of PRF on fibroblast cell behavior *in vitro*. In 2008, Lundquist was one of the first to evaluate the effects of PRF on human dermal fibroblasts.³¹ It was found that the

proliferative effect of PRF on dermal fibroblasts was significantly greater than fibrin sealant and recombinant PDGF-BB. Furthermore, PRF induced rapid release of collagen 1 and sustained release and protection against proteolytic degradation of endogenous fibrogenic factors that are important for wound healing.³¹ In a second *in vitro* study conducted by Lundquist *et al.* in 2013, PRF induced the mitogenic and migratory effect on cultured human dermal fibroblasts and they further showed that fibrocytes (a cell type important for acute wound healing) could be grown from within PRF patches, further favoring wound healing and soft tissue regeneration.³² Thereafter, Clipet *et al.* found that PRF induced fibroblast and keratinocyte cell survival and proliferation.³³ In 2015, Vahabi *et al.* also confirmed that PRF induced gingival fibroblast proliferation at 24 h; however, they found that gingival fibroblast proliferation was significantly higher in the plasma rich in the growth factors group at 48 and 72 h.³⁴ In summary, it may, therefore, be concluded that PRF is able to induce the proliferation of dermal fibroblasts, gingival fibroblasts, and keratinocytes, as well as it participates in their production of extracellular matrix collagen 1 synthesis.

Effects of PRF on endothelial cell behavior. In the only *in vitro* report investigating the effects of PRF on angiogenesis *in vitro*, Roy *et al.* investigated the effects of PRF on endothelial cells. It was found that PRF induced endothelial

TABLE 3. *In Vivo* STUDIES EVALUATING THE EFFECTS OF PLATELET-RICH FIBRIN ON SOFT TISSUE REGENERATION AND/OR WOUND HEALING

<i>Author</i>	<i>Year</i>	<i>Model</i>	<i>Defect type</i>	<i>Healing period</i>	<i>Centrifugation protocol</i>	<i>Findings/conclusions</i>
Roy <i>et al.</i>	2011	Porcine ischemic excisional wound model	8-mm disposable punch biopsies	14 days	1100 g for 6 min (with trisodium citrate) followed by 4500 g for 25 min (with CaCl ₂)	PRF improved wound angiogenesis in chronic wounds and collagen matrix deposition.
Tunali <i>et al.</i>	2013	Rabbit soft tissue healing in the oral cavity	Mucoperiosteal flaps	3, 5, 10, 15, 30 days	3500 rpm for 15 min	PRF induced the formation of new connective tissue in a rabbit model of wound healing within 30 days.
Liu <i>et al.</i>	2013	Rabbit fat grafting in plastic and reconstructive surgery	Subcutaneous injections into the ear's auricula	4, 12, 24 weeks	3000 rpm for 10 min	The efficacy of adipose tissue implantation can be enhanced by using PRF as a therapeutic adjuvant.
Suzuki <i>et al.</i>	2013	Subcutaneous injection in rats	Subcutaneous implantation on the dorsal tissues of rats	14 days	3000 rpm for 10 min	Subcutaneous injection of growth factors extracted from PRF incorporated into a gelatin gel was found to be more effective in acceleration of wound healing than the commonly used PRP.
Li <i>et al.</i>	2013	Subcutaneous injections in nude mice	Subcutaneous implantation under the cutis	7, 14 days	2100 rpm (400 g) for 12 min	PRF readily integrated with surrounding tissues and was partially replaced with collagen fibers 2 weeks after implantation.
Soyer <i>et al.</i>	2013	Rat penile urethral repair	5 mm vertical incision in the penile urethra	24h	2400 rpm for 12 min	Use of PRF after urethral repair increased early TGF- β -R and VEGF expression in urethral tissues.
Horii <i>et al.</i>	2014	Oral mucositis induced in hamsters	Intraperitoneal injection of 5-fluorouracil followed by light scratching of the cheek pouch	5, 9, and 14 days	3000 rpm (400 g) for 10 min	The PRF group exhibited significant improvements in the size and histological features of the ulcer and in themyeloepoxidase activity.
Sun <i>et al.</i>	2014	Male rat myocardial infarctions	Regional myocardial ischemia by left coronary artery ligation	42 days	600 g for 5 min	The combination of PRF with adipose-derived MSCs improved the preservation of LV function and attenuated LV remodeling.
Chen <i>et al.</i>	2014	Maxillofacial soft tissue defects in irradiated minipigs	Right parotid gland irradiation (20 Gy)	6 months	3000 rpm (400 g) for 10 min	Both adipose-derived stem cells and PRF facilitated the repair of defects in maxillofacial soft tissue in irradiated minipigs, and their combined use was the most effective.
Reksodiputro <i>et al.</i>	2014	Porcine facial plastic and reconstructive surgery	Full-thickness (FTSG) and split-thickness (STSG) skin grafts	14, 30 days	1500 g for 15 min, 1800 g for 60 min	PRF in FTSG and STSG increased type 1 collagen formation. PRF, in addition to STSG, gave the best skin graft take.
Chen <i>et al.</i>	2015	Ventricular remodeling in rats	Acute myocardial infarction induction through left coronary artery ligation	6 weeks	400 g for 10 min	Adipose-derived mesenchymal stem cells embedded in PRF scaffolds promoted angiogenesis, preserved heart function, and improved left ventricular remodeling.

TGF- β , transforming growth factor beta; VEGF, vascular endothelial growth factor; MSC, mesenchymal stem cell; LV, left ventricular; FTSG, full-thickness skin graft; STSG, split-thickness skin graft.

TABLE 4. CLINICAL STUDIES EVALUATING THE EFFECTS OF PLATELET-RICH FIBRIN ON SOFT TISSUE REGENERATION AND/OR WOUND HEALING

Author	Year	Model	Defect type	Healing period	Centrifugation protocol	Findings/conclusions
Steenvoorde <i>et al.</i>	2008	12 patients, hard-to-heal wounds	Arterial leg ulcers, diabetic foot ulcers, and postoperative wound infections (no controls)	Varied considerably	3000 rpm (400 g) for 10 min	PRF achieved full healing or a significant reduction in wound diameter, with no adverse effects.
Danielsen <i>et al.</i>	2008	20 patients, chronic leg ulcer	Randomized observation of epithelialization of donor sites and meshed split-thickness skin autografts in chronic ulcers versus skin autografts with/without PRF	5, 8 days	3000 rpm (400 g) for 10 min	Epithelial coverage of donor wounds did not differ significantly between platelet-rich fibrin and control on day 5 (43.5% vs. 34.4%, $p = 0.65$) or day 8 (76.6% vs. 94.8%, $p = 0.17$).
Anilkumar <i>et al.</i>	2009	One patient, root coverage	7 mm of clinical attachment loss on labial surface of anterior teeth (no controls)	1 month	2700 rpm for 12 min	Complete coverage was achieved 6 months after the procedure, with excellent tissue contour and color.
O'Connell <i>et al.</i>	2008	12 patients, chronic lower-extremity ulcers	17 VLU (no controls)	Weekly visits for 12 weeks	3000 g for 10 min	Complete closure was achieved in 66.7% in the PRF group demonstrating VLU versus 44% in the nontreated VLU group.
Danielsen <i>et al.</i>	2010	51 patients, laparoscopic cholecystectomy	Randomized, PRF versus albumin	10 days	3000 rpm (400 g) for 10 min	PRF did not improve wound strength significantly compared with albumin but suppressed subcutaneous collagen synthesis and deposition during early repair of surgical wounds in humans.
Sclafani	2011	50 patients, plastic surgery	PRF used for treatment of deep nasolabial folds, volume-depleted midface regions, superficial rhytids, and acne scars (no controls)	9.9 months (range, 3–30 months).	1100 rpm for 6 min	Full patient biocompatibility. No patients reported any swelling lasting more than 5 days. Most patients were satisfied with treatment.
Sammartino <i>et al.</i>	2011	50 patients, extractions (or avulsions) for the prevention of hemorrhagic complications	168 defects, extractions with patients on anti-coagulant therapies (no controls)	9 h	400 g 18 min	The proposed protocol with PRF is a reliable therapeutic option to avoid significant bleeding after dental extractions without the suspension of anticoagulant therapy in heart surgery patients.
Sclafani <i>et al.</i>	2011	Four patients, induction of dermal collagenesis, angiogenesis, and adipogenesis	PRF injected into the deep dermis and immediate subdermis of the upper arms followed by 5 mm full-thickness biopsy collection (no controls)	10 weeks	1100 rpm for 6 min	Injection of PRF into the deep dermis and subdermis of the skin stimulates a number of positive cellular changes, including increases in collagen production and angiogenesis.

(continued)

TABLE 4. (CONTINUED)

<i>Author</i>	<i>Year</i>	<i>Model</i>	<i>Defect type</i>	<i>Healing period</i>	<i>Centrifugation protocol</i>	<i>Findings/conclusions</i>
Jorgensen <i>et al.</i>	2011	15 patients, recalcitrant chronic wounds	16 lower-extremity chronic wounds of varying etiology (no controls)	6 weeks	3000 rpm for 12 min	Authors conclude that PRF is easy to prepare and apply in the clinics, is safe, and may be a clinically effective treatment for recalcitrant chronic wounds.
Gorlero <i>et al.</i>	2012	10 patients, vaginal prolapse repair	Surgery for prolapse with recurrence (stage II or higher) (no controls)	1, 6, 12, 18, 24 months	3000 rpm for 12 min	The use of PRF for site-specific prolapse repair is associated with a good functional outcome because of the healing and mechanical properties of PRF.
Jankovic <i>et al.</i>	2012	15 patients, Miller Class I or II gingival recessions	PRF or CTG	6 months	3000 rpm (400 g) for 10 min	No difference could be found between PRF and CTG groups in gingival recession therapy, except for a greater gain in keratinized tissue width obtained in the CTG group and enhanced wound healing associated with the PRF group.
Soyer <i>et al.</i>	2013	One patient, urethracutaneous fistula repair	Use of PRF in a 3-year-old boy after hypospadias repair (no controls)	1, 3 months	400 g for 10 min	After treatment with PRF, no urethral fistula was detected. Therapy with PRF improved clinical outcomes in this case report.
Chignon-Sicard <i>et al.</i>	2012	68 patients, wound healing	Postoperative hand wounds (PRF vs. reference care with petroleum jelly mesh)	1, 2, 7, 14, 21, 28, 60 days	2700 rpm (400 g) for 12 min	PRF application on fresh postoperative hand wounds showed a median improvement of 5 days faster wound healing in comparison to control.
Jain <i>et al.</i>	2012	One patient, palatal wound healing	48 year-old man, palatal wound (no control)	7, 14, 21, 28 days	3000 rpm for 10 min	Patient showed delayed wound healing after subepithelial connective tissue graft harvestation, which was re-treated successfully with PRF.
Braccini <i>et al.</i>	2013	232 patients during liposuction	Fat tissue extracted from inner side of knees (no control)	2, 4, 6, 8 months	3400 rpm for 10 min	By offering a matricial support to angiogenesis and by stimulating the proliferation of pre-adipocytes, the PRF demonstrated a beneficial role in the cicatrization and the consolidation of an adipocyte graft.
Hoaglin and Lines	2013	100 patients, third molar extractions	200 defects, PRF placed in half, reevaluated for localized osteitis (control = no therapy)	7–10 days	2700 rpm for 10–12 min	1% of cases with PRF were infected versus 9.5% in control untreated sites. PRF may be utilized to significantly reduce osteomyelitis after third molar extractions.
Desai <i>et al.</i>	2013	One patient, facial soft tissue defect	30 year-old motorcycle accident	2, 6 weeks	3000 rpm for 10 min	Innovative technique of enhancement of skin wound healing by local application of PRF

(continued)

TABLE 4. (CONTINUED)

Author	Year	Model	Defect type	Healing period	Centrifugation protocol	Findings/conclusions
Suttapreyasri and Leepong	2013	20 patients, defect wound fill	Extraction sockets, split mouth, PRF versus blood clot	1, 2, 4, 6, 8 weeks	3000 rpm for 10 min	PRF neither influenced alveolar ridge preservation nor enhanced bone formation in the extraction socket. The use of PRF revealed some effectiveness by accelerating soft-tissue healing during the first 4 weeks.
Guinot <i>et al.</i>	2014	33 patients, urethroplasty coverage in distal hypospadias	Urethroplasties performed using Duplay's technique (no controls)	8 months (range, 6–18 months)	3000 rpm for 10 min	PRF seemed to be a safe and efficient covering technique, was reported as an additional approach to coverage for hypospadias surgery, and may help in reducing the incidence of postoperative complications when coverage healthy tissue is not available.
Zumstein <i>et al.</i>	2014	20 consecutive patients, repair of chronic rotator cuff tears	Arthroscopic treatment ±PRF	6, 12 weeks	3000 rpm (400 g) for 10 min	Arthroscopic rotator cuff repair with the application of L-PRF is technically feasible and yields higher early vascularization.
Kulkarni <i>et al.</i>	2014	18 patients, healing of free gingival graft donor sites	Palatal wound healing with PRF (control without PRF)	7, 14, 21 days	3000 rpm for 10 min	PRF as a dressing is an effective method of enhancing the healing of the palatal donor site and of, consequently, reducing postoperative morbidity.
Habesoglu <i>et al.</i>	2014	32 patients with acute traumatic ear drum perforations	PRF versus nothing was used for the repair of ear drum perforation	1 month	2700 rpm for 12 min	Here, we found that PRF is a biomaterial that quickens the healing of ear drum and that is autogenous and simply prepared. In the study group, the rate of ear drum closure was 64.3% and in the control group it was 22.2% ($p < 0.05$).
Londahl <i>et al.</i>	2015	39 patients, hard-to-heal DFU	PRF was applied weekly to DFU for up to 20 weeks (no control)	Every week up to 20 weeks	3000 g for 10 min	PRF was well tolerated, easy to use and had potential in the armamentarium of the DFU treatment.
Pathak <i>et al.</i>	2015	26 patients, oral mucosal lesions after excisions	PRF over healing areas of potentially malignant lesions	7, 15, 30, and 60 days	3000 rpm for 10 min	The results of the present study suggest that the PRF membrane is a successful coverage agent that aids in the healing of superficial oral mucosal wounds.
Ajwani <i>et al.</i>	2015	20 patients, split mouth, two- and three-wall intrabony defects	OFD ± PRF (control OFD alone)	9 months	3000 rpm (400 g) for 10 min	Adjunctive use of PRF with OFD significantly improves defect fill when compared with OFD alone.

(continued)

TABLE 4. (CONTINUED)

<i>Author</i>	<i>Year</i>	<i>Model</i>	<i>Defect type</i>	<i>Healing period</i>	<i>Centrifugation protocol</i>	<i>Findings/conclusions</i>
Yelamali and Saikrishna	2015	20 patients, split mouth, third molar extractions	Soft tissue healing after extraction, PRF versus PRP	1 week	3000 rpm for 10 min	PRF is significantly better in promoting soft tissue healing when compared with PRP.
di Lauro <i>et al.</i>	2015	Two patients, exeresis of hyperplastic gingival lesions	Exeresis of lesions and application of PRF (no control)	1, 3, 7, 14, 30 days	2700 rpm for 12 min	PRF led to rapid and good healing of soft tissues, and the authors suggest that the use of PRF can be applied to cover wounds after exeresis of oral neoformations such as hyperplastic gingival lesions.
Eren <i>et al.</i>	2015	14 patients, gingival recession	Treatment with connective tissue graft or PRF (control = CTG)	1, 6 months	3000 rpm for 10 min	PRF resulted in earlier vessel formation and tissue maturation compared with CTG.
Femminella <i>et al.</i>	2016	40 patients with one site of Miller Class I or II gingival recession	Palatal wounds covered with PRF versus palatal sponge	1, 2, 3, 4 weeks	3000 rpm for 10 min	The PRF-enriched palatal bandage significantly accelerates palatal wound healing and reduces patient morbidity.
Bayer <i>et al.</i>	2016	Bilateral gluteal wounds	Paraffin embedding and mRNA extraction (no controls)	10 days	2000 g for 10 min followed by 2000 g for 10 min	PRF induced hBD-2 (implicated in wound healing) expression when applied to experimentally generated skin wounds.
Munoz <i>et al.</i>	2016	11 patients, periodontally accelerated osteogenic orthodontics	A Wilcko's modified PAOO technique with L-PRF (no controls)	1, 2, 4, 8, 10 days	3000 rpm for 10 min	Combination with traditional bone grafts; PRF potentially accelerates wound healing and reduces postsurgical pain, inflammation, and infection.

“Bold” signifies a total of eight studies that have reported the effects of PRF in a randomized clinical trial.

VLU, venous leg ulcers; CTG, connective tissue graft; DFU, diabetic foot ulcers; OFD, open-flap debridement; PAOO, periodontally accelerated osteogenic orthodontics; PRP, platelet-rich plasma.

cell mitogenesis via the extracellular signal-regulated protein kinase activation pathway.³⁵ A slow and steady release of growth factors from their PRF matrix was observed to be releasing VEGF, a known growth factor responsible for endothelial mitogenic response. These authors provide some evidence of probable mechanisms of action of PRF matrix in healing of chronic wound ulcers.³⁵

Effect of PRF on growth factor release. It has long been observed that PRF releases an array of growth factors to the surrounding micro-environment that contributes to soft tissue wound healing.²⁴ Interestingly, in 2014, a new protocol for PRF was introduced (termed Advanced-PRF or A-PRF) whereby centrifugal forces were decreased and total spin times were increased.³⁶ By decreasing the rpm while increasing the centrifugation time in the A-PRF group, an enhanced presence of neutrophilic granulocytes in the distal part of the clot was found to be contributing to monocyte differentiation to macrophages,³⁶ a cell responsible for inducing new bone formation.^{37,38} Therefore, this article concludes with the importance of centrifugation g-force on growth factor to the surrounding environment, which may be optimized by centrifugation time and speeds.

In a study investigating growth factors released from various PRF components, Kobayashi *et al.* quantified by enzyme-linked immunosorbent assay growth factors including PDGF-AA, PDGF-AB, PDGF-BB, TGF-beta, VEGF, and insulin-like growth factor (IGF).³⁹ Each of these growth factors has a specific role in tissue regeneration.

Platelet-derived growth factor. PDGFs are essential regulators for the migration, proliferation, and survival of mesenchymal cell lineages.⁴⁰ According to the distribution of mesenchymal-cell specific receptors, they are able to induce stimulation in mesenchymal cells.⁴⁰ For this reason, PDGFs play a critical role in physiologic wound healing and have been FDA approved for the regeneration of various defects in medicine and dentistry.^{41,42} Interestingly, PDGF is naturally found in PRF clots and is produced over time by leukocytes; therefore, it is considered one of the important released bio-active growth factors secreted over time from PRF.

Transforming growth factor-beta. TGF-beta is a vast superfamily of more than 30 members known as fibrosis agents, with TGF-beta1 being the most well described in the literature.^{43,44} It is a known stimulator of proliferation of various mesenchymal cell types, including osteoblasts,⁴⁵ constituting the most powerful fibrosis agent among all cytokines.⁴⁴ It plays a prominent role in matrix molecule synthesis such as collagen1 and fibronectin, whether by osteoblasts or fibroblasts. Although its regulatory mechanisms are particularly complex, TGF-beta1 plays an active role in wound healing.^{43,44}

Vascular endothelial growth factor. VEGF is the most potent growth factor responsible for angiogenesis of tissues.⁴⁶ It has potent effects on tissue remodeling and the incorporation of VEGF alone into various bone biomaterials has demonstrated increases in new bone formation, thereby pointing to the fast and potent effects of VEGF.^{46,47}

Insulin-like growth factor. IGF is a positive regulator of proliferation and differentiation for most mesenchymal cell

types, which also act as cell-protective agents.⁴⁸ Although these cytokines are cell proliferative mediators, they also constitute the major axis of programmed cell death (apoptosis) regulation, by inducing survival signals protecting cells from many apoptotic stimuli.⁴⁸

Although many known growth factors are present within PRF clots, it remains interesting to note that further molecules are being investigated from PRF for their various roles in tissue wound healing. For example, Bayer *et al.* investigated for the first time the properties that are contained within PRF that may contribute to its anti-inflammatory/anti-microbial activities.⁴⁹ It was discovered that in human keratinocytes, PRF induced the expression of hBD-2, an anti-microbial agent necessary in the treatment of chronic and infected wounds.⁴⁹ Further *in vitro* research is necessary to characterize the potential anti-inflammatory/anti-microbial activity in PRF.

Conclusions from *in vitro* research. In total, six of seven (85.6%) reported studies demonstrate a positive effect of PRF on soft tissue cell behavior *in vitro*. In all studies, appropriate controls were utilized. It was found that PRF was able to increase cell proliferation in a number of cells implicated in soft tissue repair, induced the mitogenic activity of endothelial cells important for angiogenesis, released an array of growth factors to the surrounding micro-environment, and possessed properties leading to its anti-inflammatory and anti-microbial activity.

In vivo studies evaluating the effects of PRF on soft tissue regeneration and/or wound healing

In total, 11 studies have evaluated the effects of PRF on soft tissue wound healing and regeneration (Table 3). These studies may be classified under the following four sub-headings, including the effects of PRF on (1) wound healing and angiogenesis, (2) plastic and reconstructive purposes in the ear's auricular, (3) urethral repair, and (4) myocardial ischemia and ventricular remodeling.

Effects of PRF on wound healing and angiogenesis *in vivo*. The effects of PRF have most notably been investigated on soft tissue wound healing and angiogenesis in various animal models. In the first study, Roy *et al.* evaluated PRF after 14 days in a porcine ischemic excision wound model, where 8-mm skin biopsies were created and filled with PRF versus control.³⁵ It was found that PRF significantly improved angiogenesis in chronic wounds and collagen matrix deposition (Fig. 3).³⁵ Suzuki *et al.* further showed that PRF induced faster wound healing and angiogenesis in the dorsal tissues of rats after 14 days.⁵⁰ In another subcutaneous implantation model performed in mice, PRF readily integrated with surrounding tissues and was partially replaced with collagen fibers 2 weeks after implantation.⁵¹ Furthermore, Horii *et al.* concluded that PRF significantly spread soft tissue healing of oral mucositis in rats after a 14 day healing period (Fig. 4).⁵² Tunali *et al.* found that PRF centrifuged in titanium vials improved soft tissue wound healing in a mucoperiosteal flap defect model in rabbits 30 days after implantation.⁵³ In a model designed to regenerate the parotid gland after their irradiation in minipigs, both adipose-derived stem cells and PRF




FIG. 3. Treatment of porcine ischemic wound with PRFM. Representative digital images of excisional wounds treated or not with PRFM on days 0 and 4 postwounding. Adapted with permission from Roy *et al.*³⁵ PRFM, PRF matrix. Color images available online at www.liebertpub.com/teb

significantly sped the repair of defects in maxillofacial soft tissue in irradiated minipigs, and their combined use was more effective after a 6-month healing period.⁵⁴ In 2014, it was found that PRF increased type 1 collagen formation in full- and split-thickness flaps and improved skin graft take in

a skin graft model performed in porcine animals.⁵⁵ The totality of these studies show convincingly that PRF is able to increase soft tissue wound healing in various animal models, and reports document that this is primarily due to the increase in angiogenesis to defect sites.

Effect of PRF for plastic and reconstructive purposes in the ear's auricular *in vivo*. In one study, the effect of PRF has been combined with adipose tissue for fat pad grafting in the ear's auricular. Liu *et al.* found that after a 24 week healing period, fat grafting with PRF into the ear's auricular could be enhanced with PRF as a therapeutic adjuvant to these procedures.⁵⁶ Histological examinations showed that the implanted adipose granules were well engrafted in the group containing PRF, demonstrating a higher microvessel density 4 weeks postimplantation ($p < 0.01$).⁵⁶ At 24 weeks postimplantation, the resorption rates of implanted tissue in each group were also significantly different, with PRF demonstrating the least resorption after the study endpoints ($p < 0.01$).⁵⁶ The results from this study conclude that PRF can effectively be combined with adipose tissue as a therapeutic adjuvant offering a clinically translatable strategy for soft tissue augmentation and reconstruction of the ear.

Effects of PRF on urethral repair *in vivo*. The effect of PRF was investigated on urethral repair in one animal study. Soyer *et al.* found in a 5 mm penile urethral defect model in 18 Wistar albino rats that treatment with PRF significantly increased TGF-beta and VEGF growth factor release after 24 h.⁵⁷ These authors conclude that the use of PRF after urethral repair increases TGF- β -receptor and VEGF expression in urethral tissue and may be considered an alternative measure to improve the success of urethral repair.

Effects of PRF on the repair of myocardial ischemia and ventricular remodeling *in vivo*. The effect of PRF on the




FIG. 4. Macroscopic aspects of the cheek pouches of hamsters injected with 5-fluorouracil. The control group (A–C), the fibrin group (D–F), and the PRF group (G–I) are shown. Notice the significantly faster wound healing associated with the PRF group.⁵² Color images available online at www.liebertpub.com/teb

repair of heart-related injuries has been investigated in two studies. Sun *et al.* first demonstrated that the combination of PRF with adipose derived MSCs improved the preservation of left ventricular (LV) function and attenuated LV remodeling in a rat model that induced regional myocardial ischemia by left coronary artery ligation.⁵⁸ Furthermore, in 2015, adipose-derived MSCs were embedded in PRF scaffolds to investigate its effect on angiogenesis in heart tissues.⁵⁹ It was found that the combination of PRF with adipose cells promoted angiogenesis, preserved heart function, and reduced LV remodeling in rat acute myocardial infarction when compared with controls (Fig. 5).⁵⁹ It may, therefore, be concluded that in both studies, the additional use of PRF led to improved heart function and angiogenesis; however, both research groups point to the fact that further study is necessary before these findings may be translated to clinical use.

Conclusions from *in vivo* research. In total, 11 studies found that PRF significantly improved soft tissue regeneration,

wound healing, and/or angiogenesis in various animal models investigated. In all studies, appropriate controls were utilized. It was found that PRF was able to promote soft tissue wound healing in various wound-healing models by promoting local angiogenesis to defect sites, could be combined with adipose tissue/cells to further improve regeneration, could successfully be utilized for urethral repair, and led to improvements in myocardial ischemia and ventricular remodeling.

Clinical studies evaluating the effects of PRF on soft tissue regeneration and/or wound healing

In total, 31 studies investigated the effects of PRF on soft tissue wound healing/regeneration in various clinical scenarios. Table 4 presents a summary of each of the outcomes found in each of the clinical studies, with italicization denoting randomized clinical studies with appropriate controls. The use of PRF has been utilized for 20 different clinical procedures; 7 of which come from the oral and maxillofacial




FIG. 5. Illustration of IVIS study and anatomical and pathological findings on day 42 after AMI induction ($n=8$). (A) Serial assessments of living imaging by IVIS after AMI. (B) The anatomical findings showed the cross-sectional area of the heart at the papillary muscle (blue arrowheads) among the four groups. The LV chamber size was the highest in the AMI group, lowest in the sham-control group, and notably higher in the AMI+PRF group than in AMI+PRF+ADMSC; conversely, the infarct size showed an opposite pattern of LV chamber size. The black arrowheads indicated PRF scaffold tissue in the AMI+PRF group and ADMSC-embedded PRF scaffold (AMI+PRF+ADMSC) (i.e., engineered ADMSC grafts) group, whereas the green arrowheads show the wall thickness in the infarct area. Scale bars=5 mm. (C) *versus other groups with different symbols (*, †, ‡, §), $p<0.001$. Statistical analysis using one-way analysis of variance, followed by Bonferroni multiple-comparison *post hoc* test. Symbols (*, †, ‡, §) indicate significance (at 0.05 level). Adapted with permission from Chen *et al.*⁵⁹ IVIS, *in vivo* imaging system; AMI, acute myocardial infarction; LV, left ventricular; ADMSC, adipose-derived mesenchymal stem cell. Color images available online at www.liebertpub.com/teb

region (Table 4). In the dental field, the most commonly utilized use of PRF was for the treatment of extraction sockets,^{60–63} gingival recessions,^{64–66} and palatal wound closure^{67–69} with PRF being additionally utilized for the repair of potentially malignant lesions,⁷⁰ regeneration of periodontal defects,⁷¹ hyperplastic gingival tissues,⁷² and in addition to periodontally accelerated osteogenic orthodontics.⁷³ In other medical procedures, the use of PRF has been mostly combined for the successful management of hard-to-heal leg ulcers, including diabetic foot ulcers, venous leg ulcers, and chronic leg ulcers.^{74–78} Furthermore, PRF has been investigated for the management of hand ulcers,⁷⁹ facial soft tissue defects,⁸⁰ laparoscopic cholecystectomy,⁸¹ in plastic surgery for the treatment of deep nasolabial folds, volume-depleted midface regions, facial defects, superficial rhytids and acne scars,⁸² induction of dermal collagenesis,⁸³ vaginal prolapse repair,⁸⁴ urethracutaneous fistula repair,^{85,86} during liposuction surgical procedures,⁸⁷ chronic rotator cuff tears,⁸⁸ and acute traumatic ear drum perforations.⁸⁹ A total of eight studies have reported the effects of PRF in a randomized clinical trial (Table 4, bolded). Five nonrandomized studies reported appropriately selected controls, whereas 18 studies (58% of the total listed clinical studies) reported no controls in their investigation and instead focused on the technical utilization/aspects of combining PRF during their various medical procedures. In total, 9 of the 13 studies utilizing appropriate controls reported a significant positive influence combining PRF to their surgical protocols during soft tissue wound healing (Table 4). In total, 27 of the 31 studies (87%) reported having beneficial effects for the utilization of PRF during soft tissue regeneration and/or soft tissue wound healing and angiogenesis in human applications. Noteworthy, 18 of 31 studies (58%) did not use appropriate controls in their clinical studies.

Discussion and Future Perspectives

Platelet concentrates, including PRP and PRF, have been used for regenerative procedures in various fields of medicine, including dentistry, reconstructive surgery, plastic surgery, and dermatology, to deliver supranatural concentrations of autologous growth factors directly to host tissues. These growth factors have been shown to be chemotactic for various cell types, including monocytes, fibroblasts, endothelial cells, stem cells, and fibroblasts, creating tissue micro-environments and directly influencing the proliferation and differentiation of progenitor cells.⁹⁰ Furthermore, platelet concentrates are safe, reliable, and cost-effective means to accelerate tissue healing and for improving the efficiency of tissue repair after injury.

In the present study, we investigated specifically the regenerative potential of soft tissue after use of PRF. To date, no systematic review has characterized the regenerative potential of PRF specifically for soft tissue wound-healing/regeneration, despite the great number of *in vitro*, *in vivo*, and clinical studies that have been reported on this topic to date. Although a large number of research to date has focused on the effects of PRP on various wound-healing events such as tendon regeneration,^{91–95} this systematic review article focused specifically on the regenerative potential of PRF for soft tissue management and excluded all

studies where PRF was utilized for bone, cartilage, or tendon regeneration. In total, 48 studies met our inclusion criteria, with 31 studies being derived from human clinical studies (Table 4).

Although the effects of PRF were shown to enhance soft tissue regeneration in all but one *in vitro* and *in vivo* study (18 studies total), the results from the clinical studies need to be interpreted with caution. In total, 18 of the 31 clinical studies (58%) report a beneficial effect of PRF based on the investigators' reported clinical experience; however, in these studies, no controls were utilized and the authors instead focused primarily on their case reports/case series (Table 4). In contrast, all *in vitro* and *in vivo* studies utilized appropriate controls. It may, therefore, be concluded that this first wave of research provides the clinical evidence that PRF seems to promote soft tissue wound healing; however, it is clear that future human studies are needed to systematically compare the effects of PRF in a randomized, controlled fashion across a wide range of medical fields.

Similarly, it was recently reported in a systematic review that the effects of platelet concentrates showed similar findings on bone healing/formation of extraction sockets and intrabony defects (Fig. 6).^{96,97} Although the results of that meta-analysis are suggestive that platelet concentrates increase new bone formation in postextraction sockets, the authors report that due to the limited amount and quality of the available evidence, these results need to be cautiously interpreted.⁹⁶ It was reported that a standardization of the experimental design was necessary for a better understanding of the true effects of the use of platelet concentrates for enhancing postextraction socket healing.⁹⁶ Within the limits of our review article, we conclude similar findings that the effects of PRF enhance soft tissue regeneration; however, future studies on soft tissue regeneration after use of PRF need to be designed with appropriate controls and these findings need also to be interpreted with caution until further randomized clinical trials are gathered.

One of the reported advantages of PRF was the ability for the fibrin network containing leukocytes to resist and fight infection. Chronic nonhealing wounds are a significant medical challenge and the pathogenesis of nonhealing wounds, therefore, requires new treatment options to improve clinical outcomes. One of the main factors to date hypothesized to further speed the wound-healing properties of PRF in comparison to PRP is the fact that it contains higher levels of WBCs that favor the continuous release of growth factors. Recently, we demonstrated that both PRF and the new formulation of PRF termed A-PRF were able to release significantly higher levels of growth factors when compared with PRP over a 10-day period.³⁹ Furthermore, macrophages have been shown to be key players during tissue regeneration, wound healing, and prevention of infection.^{28,37,38} Furthermore, they contain antimicrobial effects that are capable of reducing bacterial contamination after surgeries.²⁸ This finding was best exemplified in the healing of third molar extraction sockets.⁶¹ It was reported that infection (osteomyelitis) is commonly reported in 9.5% of wisdom tooth removal and when a PRF plug was inserted after extraction, this was significantly reduced to 1% of cases.⁶¹ Despite these reported findings, very little is yet known what the antibacterial properties of PRF are, as very little/few studies have investigated this phenomenon.⁹⁸



FIG. 6. Clinical diagram of intrabony defect regeneration with PRF. Notice the initial lesions and soft tissue recessions that have successfully been regenerated after application with PRF. Adapted with permission from Anuroopa *et al.*⁹⁷ Color images available online at www.liebertpub.com/teb

From a tissue-engineering standpoint, it remains interesting to note that no research to date has focused on the strength, stiffness, or toughness of PRF despite its clinical use for more than 15 years. Therefore, it remains of interest to better characterize its biomaterial properties and future research should focus on what factors might further improve its characteristics for various biomedical applications. For instance, it may be that for cartilage regeneration, versus ligament repair versus periodontal soft tissue management that variations of PRF may be further modified depending on the tensile demands and requirements of the defect. As currently only one centrifugation protocol of PRF is utilized for clinical use, it remains of interest to further study how modifications in centrifugation speeds and time might affect the biomechanical properties of PRF for various medical applications.

Furthermore, to date, very little is known regarding the effects of the fibrin architecture and leukocyte content from these products, as both these components are too often neglected as contributing factors in the tissue regenerative potential of PRF. The presence of leukocytes has a great impact on the biology of wound healing,^{17,30} not only due to their additional release of growth factors and their implications in antibacterial immune defense but also because they are key regulators controlling the wound-healing environment through local factor regulation. Future basic research should focus specifically on the contribution of these cells in specific cell knock-down/knock-in systems to determine the functional roles of each cell in the wound-healing process when PRF is utilized. For instance, it has been reported that addition of activated macrophage to wounds in aging mice and humans accelerated healing time.²⁸ Thus, in theory, the concept of developing newer modified protocols of PRF to further increase the number of WBCs would, in principle, increase wound repair. Nevertheless, a better understanding of the individual roles of the various cells found in PRF could prove to be an important finding for the development of these technologies, leading to

modern changes to their protocols and further increasing their regenerative potential.

Conclusion

In summary, two main findings can be drawn from the present systematic review: (1) The currently available literature supports soft tissue regeneration after soft tissue regenerative procedures utilizing PRF; and (2) there is a lack of appropriate controls to the majority of studies drawing conclusive evidence that PRF is able to further, as most of the clinical studies to date thus far highlight the use of PRF in case series experiments or retrospective analysis without comparative results to appropriate controls. Therefore, it is imperative that the next wave of research utilizing PRF as an adjunct to soft tissue regenerative therapies designs appropriate studies with necessary controls to further evaluate the regenerative potential of PRF for soft tissue wound healing.

Disclosure Statement

No competing financial interest exist.

References

1. Coury, A.J. Expediting the transition from replacement medicine to tissue engineering. *Regen Biomater* **3**, 111, 2016.
2. Dai, R., *et al.* Adipose-derived stem cells for tissue engineering and regenerative medicine applications. *Stem Cells Int* **2016**, 6737345, 2016.
3. Rouwkema, J., and Khademhosseini, A. Vascularization and angiogenesis in tissue engineering: beyond creating static networks. *Trends Biotechnol* **34**, 733, 2016.
4. Zhu, W., *et al.* 3D printing of functional biomaterials for tissue engineering. *Curr Opin Biotechnol* **40**, 103, 2016.
5. Upputuri, P.K., *et al.* Recent developments in vascular imaging techniques in tissue engineering and regenerative medicine. *Biomed Res Int* **2015**, 783983, 2015.
6. Guo, S., and Dipietro L.A. Factors affecting wound healing. *J Dent Res* **89**, 219, 2010.

7. Gosain, A., and DiPietro, L.A. Aging and wound healing. *World J Surg* **28**, 321, 2004.
8. Eming, S.A., *et al.* Regulation of angiogenesis: wound healing as a model. *Prog Histochem Cytochem* **42**, 115, 2007.
9. Eming, S.A., *et al.* [Chronic wounds. Novel approaches in research and therapy]. *Hautarzt* **58**, 939, 2007 (Article in German).
10. Garraud, O., and Cognasse, F. Are platelets cells? And if yes, are they immune cells? *Front Immunol* **6**, 70, 2015.
11. Nurden, A.T. Platelets, inflammation and tissue regeneration. *Thromb Haemost* **105 Suppl 1**, S13, 2011.
12. Heyns Adu, P., *et al.* Zinc-induced platelet aggregation is mediated by the fibrinogen receptor and is not accompanied by release or by thromboxane synthesis. *Blood* **66**, 213, 1985.
13. Marx, R.E., *et al.* Platelet-rich plasma: growth factor enhancement for bone grafts. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* **85**, 638, 1998.
14. Peerbooms, J.C., *et al.* Use of platelet rich plasma to treat plantar fasciitis: design of a multi centre randomized controlled trial. *BMC Musculoskelet Disord* **11**, 69, 2010.
15. Rozman, P., and Bolta, Z. Use of platelet growth factors in treating wounds and soft-tissue injuries. *Acta Dermatovenol Alp Pannonica Adriat* **16**, 156, 2007.
16. Alsousou, J., *et al.* The biology of platelet-rich plasma and its application in trauma and orthopaedic surgery: a review of the literature. *J Bone Joint Surg Br* **91**, 987, 2009.
17. Davis, V.L., *et al.* Platelet-rich preparations to improve healing. Part I: workable options for every size practice. *J Oral Implantol* **40**, 500, 2014.
18. De Pascale, M.R., *et al.* Platelet derivatives in regenerative medicine: an update. *Transfus Med Rev* **29**, 52, 2015.
19. Grambart, S.T. Sports medicine and platelet-rich plasma: nonsurgical therapy. *Clin Podiatr Med Surg* **32**, 99, 2015.
20. Whitman, D.H., Berry, R.L., and Green, D.M. Platelet gel: an autologous alternative to fibrin glue with applications in oral and maxillofacial surgery. *J Oral Maxillofac Surg* **55**, 1294, 1997.
21. Borzini, P., *et al.* Platelet gel—the Italian way: a call for procedure standardization and quality control. *Transfus Med* **16**, 303, 2006.
22. Choukroun, J., *et al.* Platelet-rich fibrin (PRF): a second-generation platelet concentrate. Part IV: clinical effects on tissue healing. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* **101**, e56, 2006.
23. Dohan, D.M., *et al.* Platelet-rich fibrin (PRF): a second-generation platelet concentrate. Part I: technological concepts and evolution. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* **101**, e37, 2006.
24. Dohan, D.M., *et al.* Platelet-rich fibrin (PRF): a second-generation platelet concentrate. Part II: platelet-related biologic features. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* **101**, e45, 2006.
25. Dohan, D.M., *et al.* Platelet-rich fibrin (PRF): a second-generation platelet concentrate. Part III: leucocyte activation: a new feature for platelet concentrates? *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* **101**, e51, 2006.
26. Martin, P., and Leibovich, S.J. Inflammatory cells during wound repair: the good, the bad and the ugly. *Trends Cell Biol* **15**, 599, 2005.
27. Tsirogianni, A.K., Moutsopoulos, N.M., and Moutsopoulos, H.M. Wound healing: immunological aspects. *Injury* **37 Suppl 1**, S5, 2006.
28. Adamson, R. Role of macrophages in normal wound healing: an overview. *J Wound Care* **18**, 349, 2009.
29. Davis, V.L., *et al.* Platelet-rich preparations to improve healing. Part II: platelet activation and enrichment, leukocyte inclusion, and other selection criteria. *J Oral Implantol* **40**, 511, 2014.
30. Ghasemzadeh, M., and Hosseini, E. Intravascular leukocyte migration through platelet thrombi: directing leukocytes to sites of vascular injury. *Thromb Haemost* **113**, 1224, 2015.
31. Lundquist, R., Dziegiel, M.H., and Agren, M.S. Bioactivity and stability of endogenous fibrogenic factors in platelet-rich fibrin. *Wound Repair Regen* **16**, 356, 2008.
32. Lundquist, R., *et al.* Characteristics of an autologous leukocyte and platelet-rich fibrin patch intended for the treatment of recalcitrant wounds. *Wound Repair Regen* **21**, 66, 2013.
33. Clipet, F., *et al.* In vitro effects of Choukroun's platelet-rich fibrin conditioned medium on 3 different cell lines implicated in dental implantology. *Implant Dent* **21**, 51, 2012.
34. Vahabi, S., *et al.* Effects of plasma rich in growth factors and platelet-rich fibrin on proliferation and viability of human gingival fibroblasts. *J Dent (Tehran)* **12**, 504, 2015.
35. Roy, S., *et al.* Platelet-rich fibrin matrix improves wound angiogenesis via inducing endothelial cell proliferation. *Wound Repair Regen* **19**, 753, 2011.
36. Ghanaati, S., *et al.* Advanced platelet-rich fibrin: a new concept for cell-based tissue engineering by means of inflammatory cells. *J Oral Implantol* **40**, 679, 2014.
37. Miron, R.J., and Bosshardt, D.D. OsteoMacs: key players around bone biomaterials. *Biomaterials* **82**, 1, 2016.
38. Sinder, B.P., Pettit, A.R., and McCauley, L.K. Macrophages: their emerging roles in bone. *J Bone Miner Res* **30**, 2140, 2015.
39. Kobayashi, E., *et al.* Comparative release of growth factors from PRP, PRF, and advanced-PRF. *Clin Oral Investig* 2016. [Epub ahead of print]; DOI: 10.1007/s00784-016-1719-1.
40. Ng, F., *et al.* PDGF, TGF- β , and FGF signaling is important for differentiation and growth of mesenchymal stem cells (MSCs): transcriptional profiling can identify markers and signaling pathways important in differentiation of MSCs into adipogenic, chondrogenic, and osteogenic lineages. *Blood* **112**, 295, 2008.
41. Pierce, G., *et al.* Detection of platelet-derived growth factor (PDGF)-AA in actively healing human wounds treated with recombinant PDGF-BB and absence of PDGF in chronic nonhealing wounds. *J Clin Invest* **96**, 1336, 1995.
42. Howell, T.H., *et al.* A phase I/II clinical trial to evaluate a combination of recombinant human platelet-derived growth factor-BB and recombinant human insulin-like growth factor-I in patients with periodontal disease. *J Periodontol* **68**, 1186, 1997.
43. Border, W.A., and Noble, N.A. Transforming growth factor beta in tissue fibrosis. *N Engl J Med* **331**, 1286, 1994.
44. Bowen, T., Jenkins, R.H., and Fraser, D.J. MicroRNAs, transforming growth factor beta-1, and tissue fibrosis. *J Pathol* **229**, 274, 2013.
45. Roberts, A.B., *et al.* Transforming growth factor β biochemistry and roles in embryogenesis, tissue repair and remodeling, and carcinogenesis. In *Recent Progress in Hormone Research: Proceedings of the 1987 Laurentian Hormone Conference*. San Diego, CA: Academic Press, 2013, pp. 157.
46. Shamloo, A., Xu, H., and Heilshorn, S. Mechanisms of vascular endothelial growth factor-induced pathfinding by

- endothelial sprouts in biomaterials. *Tissue Eng Part A* **18**, 320, 2012.
47. Leach, J.K., *et al.* Coating of VEGF-releasing scaffolds with bioactive glass for angiogenesis and bone regeneration. *Biomaterials* **27**, 3249, 2006.
 48. Giannobile, W.V., *et al.* Comparative effects of platelet-derived growth factor-BB and insulin-like growth factor-I, individually and in combination, on periodontal regeneration in *Macaca fascicularis*. *J Periodontol Res* **31**, 301, 1996.
 49. Bayer, A., *et al.* Platelet-released growth factors induce the antimicrobial peptide human beta-defensin-2 in primary keratinocytes. *Exp Dermatol* **25**, 460, 2016.
 50. Suzuki, S., Morimoto, N., and Ikada, Y. Gelatin gel as a carrier of platelet-derived growth factors. *J Biomater Appl* **28**, 595, 2013.
 51. Li, Q., *et al.* Platelet-rich fibrin promotes periodontal regeneration and enhances alveolar bone augmentation. *Biomed Res Int* **2013**, 638043, 2013.
 52. Horii, K., *et al.* Platelet-rich fibrin has a healing effect on chemotherapy-induced mucositis in hamsters. *Oral Surg Oral Med Oral Pathol Oral Radiol* **117**, 445, 2014.
 53. Tunali, M., *et al.* In vivo evaluation of titanium-prepared platelet-rich fibrin (T-PRF): a new platelet concentrate. *Br J Oral Maxillofac Surg* **51**, 438, 2013.
 54. Chen, Y., *et al.* Improvement in the repair of defects in maxillofacial soft tissue in irradiated minipigs by a mixture of adipose-derived stem cells and platelet-rich fibrin. *Br J Oral Maxillofac Surg* **52**, 740, 2014.
 55. Reksodiputro, M., *et al.* PRFM enhance wound healing process in skin graft. *Facial Plast Surg* **30**, 670, 2014.
 56. Liu, B., *et al.* The adjuvant use of stromal vascular fraction and platelet-rich fibrin for autologous adipose tissue transplantation. *Tissue Eng Part C Methods* **19**, 1, 2013.
 57. Soyer, T., *et al.* The effect of platelet rich fibrin on growth factor levels in urethral repair. *J Pediatr Surg* **48**, 2545, 2013.
 58. Sun, C.K., *et al.* Direct implantation versus platelet-rich fibrin-embedded adipose-derived mesenchymal stem cells in treating rat acute myocardial infarction. *Int J Cardiol* **173**, 410, 2014.
 59. Chen, Y.L., *et al.* Adipose-derived mesenchymal stem cells embedded in platelet-rich fibrin scaffolds promote angiogenesis, preserve heart function, and reduce left ventricular remodeling in rat acute myocardial infarction. *Am J Transl Res* **7**, 781, 2015.
 60. Sammartino, G., *et al.* Prevention of hemorrhagic complications after dental extractions into open heart surgery patients under anticoagulant therapy: the use of leukocyte- and platelet-rich fibrin. *J Oral Implantol* **37**, 681, 2011.
 61. Hoaglin, D.R., and Lines, G.K. Prevention of localized osteitis in mandibular third-molar sites using platelet-rich fibrin. *Int J Dent* **2013**, 875380, 2013.
 62. Suttapreyasri, S., and Leepong, N. Influence of platelet-rich fibrin on alveolar ridge preservation. *J Craniofac Surg* **24**, 1088, 2013.
 63. Yelamali, T., and Saikrishna, D. Role of platelet rich fibrin and platelet rich plasma in wound healing of extracted third molar sockets: a comparative study. *J Maxillofac Oral Surg* **14**, 410, 2015.
 64. Anilkumar, K., *et al.* Platelet-rich-fibrin: a novel root coverage approach. *J Indian Soc Periodontol* **13**, 50, 2009.
 65. Jankovic, S., *et al.* Use of platelet-rich fibrin membrane following treatment of gingival recession: a randomized clinical trial. *Int J Periodontics Restorative Dent* **32**, e41, 2012.
 66. Eren, G., *et al.* Cytokine (interleukin-1beta) and MMP levels in gingival crevicular fluid after use of platelet-rich fibrin or connective tissue graft in the treatment of localized gingival recessions. *J Periodontol Res* **51**, 481, 2016.
 67. Jain, V., *et al.* Role of platelet-rich-fibrin in enhancing palatal wound healing after free graft. *Contemp Clin Dent* **3(Suppl 2)**, S240, 2012.
 68. Kulkarni, M.R., *et al.* Platelet-rich fibrin as an adjunct to palatal wound healing after harvesting a free gingival graft: a case series. *J Indian Soc Periodontol* **18**, 399, 2014.
 69. Femminella, B., *et al.* Clinical comparison of platelet-rich fibrin and a gelatin sponge in the management of palatal wounds after epithelialized free gingival graft harvest: a randomized clinical trial. *J Periodontol* **87**, 103, 2016.
 70. Pathak, H., *et al.* Treatment of oral mucosal lesions by scalpel excision and platelet-rich fibrin membrane grafting: a review of 26 sites. *J Oral Maxillofac Surg* **73**, 1865, 2015.
 71. Ajwani, H., *et al.* Comparative evaluation of platelet-rich fibrin biomaterial and open flap debridement in the treatment of two and three wall intrabony defects. *J Int Oral Health* **7**, 32, 2015.
 72. di Lauro, A.E., *et al.* Soft tissue regeneration using leukocyte-platelet rich fibrin after exeresis of hyperplastic gingival lesions: two case reports. *J Med Case Rep* **9**, 252, 2015.
 73. Munoz, F., *et al.* Use of leukocyte and platelet-rich fibrin (L-PRF) in periodontally accelerated osteogenic orthodontics (PAOO): clinical effects on edema and pain. *J Clin Exp Dent* **8**, e119, 2016.
 74. Danielsen, P., *et al.* Effect of topical autologous platelet-rich fibrin versus no intervention on epithelialization of donor sites and meshed split-thickness skin autografts: a randomized clinical trial. *Plast Reconstr Surg* **122**, 1431, 2008.
 75. O'Connell, S.M., *et al.* Autologous platelet-rich fibrin matrix as cell therapy in the healing of chronic lower-extremity ulcers. *Wound Repair Regen* **16**, 749, 2008.
 76. Steenvoorde, P., *et al.* Use of autologous platelet-rich fibrin on hard-to-heal wounds. *J Wound Care* **17**, 60, 2008.
 77. Jorgensen, B., *et al.* A pilot study to evaluate the safety and clinical performance of leucopatch, an autologous, additive-free, platelet-rich fibrin for the treatment of recalcitrant chronic wounds. *Int J Low Extrem Wounds* **10**, 218, 2011.
 78. Londahl, M., *et al.* Use of an autologous leukocyte and platelet-rich fibrin patch on hard-to-heal DFUs: a pilot study. *J Wound Care* **24**, 172, 2015.
 79. Chignon-Sicard, B., *et al.* Efficacy of leukocyte- and platelet-rich fibrin in wound healing: a randomized controlled clinical trial. *Plast Reconstr Surg* **130**, 819e, 2012.
 80. Desai, C.B., *et al.* Use of platelet-rich fibrin over skin wounds: modified secondary intention healing. *J Cutan Aesthet Surg* **6**, 35, 2013.
 81. Danielsen, P.L., Agren, M.S., and Jorgensen, L.N. Platelet-rich fibrin versus albumin in surgical wound repair: a randomized trial with paired design. *Ann Surg* **251**, 825, 2010.
 82. Sclafani, A.P. Safety, efficacy, and utility of platelet-rich fibrin matrix in facial plastic surgery. *Arch Facial Plast Surg* **13**, 247, 2011.
 83. Sclafani, A.P., and McCormick, S.A. Induction of dermal collagenesis, angiogenesis, and adipogenesis in human skin by injection of platelet-rich fibrin matrix. *Arch Facial Plast Surg* **14**, 132, 2012.

84. Gorlero, F., *et al.* New approach in vaginal prolapse repair: mini-invasive surgery associated with application of platelet-rich fibrin. *Int Urogynecol J* **23**, 715, 2012.
85. Soyer, T., *et al.* Use of autologous platelet rich fibrin in urethracutaneous fistula repair: preliminary report. *Int Wound J* **10**, 345, 2013.
86. Guinot, A., *et al.* Preliminary experience with the use of an autologous platelet-rich fibrin membrane for urethroplasty coverage in distal hypospadias surgery. *J Pediatr Urol* **10**, 300, 2014.
87. Braccini, F., *et al.* Modern lipostructure: the use of platelet rich fibrin (PRF). *Rev Laryngol Otol Rhinol (Bord)* **134**, 231, 2013.
88. Zumstein, M.A., *et al.* Increased vascularization during early healing after biologic augmentation in repair of chronic rotator cuff tears using autologous leukocyte- and platelet-rich fibrin (L-PRF): a prospective randomized controlled pilot trial. *J Shoulder Elbow Surg* **23**, 3, 2014.
89. Habesoglu, M., *et al.* Platelet-rich fibrin plays a role on healing of acute-traumatic ear drum perforation. *J Craniofac Surg* **25**, 2056, 2014.
90. Scalfani, A.P., *et al.* Modulation of wound response and soft tissue ingrowth in synthetic and allogeneic implants with platelet concentrate. *Arch Facial Plast Surg* **7**, 163, 2005.
91. Andia, I., and Abate, M. Platelet-rich plasma in the treatment of skeletal muscle injuries. *Expert Opin Biol Ther* **15**, 987, 2015.
92. Cai, Y.Z., Zhang, C., and Lin, X.J. Efficacy of platelet-rich plasma in arthroscopic repair of full-thickness rotator cuff tears: a meta-analysis. *J Shoulder Elbow Surg* **24**, 1852, 2015.
93. Figueroa, D., *et al.* Platelet-rich plasma use in anterior cruciate ligament surgery: systematic review of the literature. *Arthroscopy* **31**, 981, 2015.
94. Zhao, J.G., *et al.* Platelet-rich plasma in arthroscopic rotator cuff repair: a meta-analysis of randomized controlled trials. *Arthroscopy* **31**, 125, 2015.
95. Hudgens, J.L., *et al.* Platelet-rich plasma activates proinflammatory signaling pathways and induces oxidative stress in tendon fibroblasts. *Am J Sports Med* **44**, 1931, 2016.
96. Del Fabbro, M., *et al.* Autologous platelet concentrate for post-extraction socket healing: a systematic review. *Eur J Oral Implantol* **7**, 333, 2014.
97. Anuroopa, P., *et al.* Role and efficacy of L-PRFmatrix in the regeneration of periodontal defect: a new perspective. *J Clin Diagn Res* **8**, Z403, 2014.
98. Cieslik-Bielecka, A., *et al.* Microbicidal properties of leukocyte- and platelet-rich plasma/fibrin (L-PRP/L-PRF): new perspectives. *J Biol Regul Homeost Agents* **26(2 Suppl 1)**, 43s, 2012.

Address correspondence to:
Richard J. Miron, DDS, PhD
Department of Periodontology
Nova Southeastern University
Fort Lauderdale, FL 33328

E-mail: rmiron@nova.edu

Received: June 10, 2016

Accepted: September 12, 2016

Online Publication Date: October 10, 2016